Rate My Professor Nick Lintzeris

Lintzeris's research focuses on developing and evaluating treatment interventions and pharmacotherapies for substance use disorders, including opioid dependence, cannabis use disorder, benzodiazepine dependence, and psychostimulant use. He has produced over 200 peer-reviewed publications and contributed to clinical guidelines, such as the Long-acting injectable buprenorphine (LAIB) for opioid dependence treatment practice guide (2024, co-authored with Professor Adrian Dunlop). Key publications include The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia (2024, Medical Journal of Australia), Patient-Reported Outcomes of Treatment of Opioid Dependence with Buprenorphine-Naloxone vs Methadone in a Multicentre Randomised Trial (2021, JAMA Network Open), and Medicinal Cannabis Prescribing in Australia: An Analysis of Trends (2022). His work encompasses clinical trials on medicinal cannabis, systematic reviews, health systems research, and epidemiology, often funded by bodies like the National Health and Medical Research Council. Lintzeris bridges clinical practice and research, collaborating with Australian and UK teams to translate evidence into service improvements, and engages in teaching, supervision, and professional leadership in addiction medicine.